MyelinWatch EL
← Pipeline
Late preclinicalAnnounced / plannedNo efficacy data yet

Translational / Phase 1 preparation

Low-dose theophylline patch

Transdermal low-dose theophylline • HDAC2 activation

Practical availability: Preclinical — not available as a clinical intervention

Compound / intervention
Transdermal low-dose theophylline • HDAC2 activation
Mechanism
Low-dose theophylline; HDAC2 activation
Development stage
Translational / Phase 1 preparation
Status
ForTra-funded GMP/patch optimisation • Phase 1 in healthy volunteers planned
Evidence level
No human MS efficacy data • preclinical mechanism + formulation development
Next substantive checkpoint

Optimised patch validation, GMP manufacture and first-in-human safety/PK; public trial registration

University / investigatorOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

Late preclinicalAnnounced / plannedNo efficacy data yet

Translational

Low-dose theophylline patch receives funding for GMP development and Phase 1 preparation

Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to move a low-dose transdermal theophylline patch toward industrial and GMP production and a planned Phase 1 study in healthy volunteers. The approach targets HDAC2 and has a preclinical rationale for myelin repair.

Practical availability: Preclinical — not available as a clinical intervention

What this means clinically

The funding narrows the translational gap, but Phase 1 is not yet publicly registered and there are no efficacy data in people with MS.

Source quality: Official university update plus peer-reviewed formulation work

University / investigatorJohannes Gutenberg University Mainz ↗